<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04396912</url>
  </required_header>
  <id_info>
    <org_study_id>B.10.1TKH.4.34.H.GP0.01/1</org_study_id>
    <nct_id>NCT04396912</nct_id>
  </id_info>
  <brief_title>Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort</brief_title>
  <official_title>Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umraniye Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umraniye Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study, the severity of recurrent laryngeal nerve injury (RLNI) and
      hypocalcemia (H) will be followed-up and the probable interrelation between them will be
      proposed considering the clinical situation of patients, e.g. improvement in hypocalcemia
      also make a positive effect on voice? (any objective sign? Ca? PTH?), return of voice is
      parallel with the improvement in hypocalcemia? Postoperative calcium (Ca), parathyroid
      hormone (PTH), regular vocal cord evaluations by ear-nose-throat (ENT) exams,
      deterioration-stability-improvement of clinical symptoms regarding both Ca metabolism and
      vocal cord function will be noted at regular intervals (postoperative day 1-3-first, weekly
      control/first month, monthly/first 6-month, 3-monthly/6-12 months) at outpatient controls.
      Serum Ca, PTH, ENT evaluation of vocal cords-noted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total thyroidectomy is currently the preferred surgical treatment modality for both thyroid
      carcinomas and benign disorders such as multinodular goitre, since it minimizes the risk of
      recurrence and eliminates the complication risks of repeat or completion surgery. Vocal cord
      paralysis due to injury to recurrent laryngeal nerve (RLN) is the most dreaded complication
      of total thyroidectomy. The reported incidence of temporary RLN injury (RLNI) varies between
      0 and 12 %, while the incidence of permanent RLNI has been reported to be much lower (0-3.5
      %). In case of bilateral RLNI, respiratory distress and aspiration can develop rapidly and
      may result in mortality. Therefore, all precautions including close monitoring and
      tracheostomy should be undertaken without any delay. The best known technique to avoid injury
      to RLN is meticulous dissection of the nerve throughout its anatomic pathway. However,
      functional impairment of RLN is not visible macroscopically and intraoperative nerve
      monitoring (IONM) has been developed to monitor the nerve to avoid unnecessary dissection.
      Meticulous hemostasis can be achieved with harmonic sealing instrument, since improper
      hemostasis is known to increase the risk of RLNI. Despite the lack of evidence to support an
      advantage of IONM over the standard anatomic dissection of RLN, surgeons have adopted it in
      increasing ratios. The second most feared compliation of thyroidectomy is iatrogenic
      hypocalcemia. Transient symptomatic hypocalcemia after total thyroidectomy occurs in
      approximately 7% to 25% of cases, but permanent hypocalcemia is less common (0.4% to 13.8%).
      Size and invasion of tumor, operative trauma and vascular compromise determines the severity
      of symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>s/p TT- normal (no complication)</measure>
    <time_frame>June 01, 2020-June 01, 2021</time_frame>
    <description>TT: total thyroidectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>s/p TT+VCP</measure>
    <time_frame>June 01, 2020-June 01, 2021</time_frame>
    <description>VCP: vocal cord paralysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>s/p TT+H</measure>
    <time_frame>June 01, 2020-June 01, 2021</time_frame>
    <description>H: hypocalcemia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>s/p TT+VCP+H</measure>
    <time_frame>June 01, 2020-June 01, 2021</time_frame>
    <description>Any improvement recorded? VCP? H? vice versa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in vocal cord function /serum calcium</measure>
    <time_frame>June 01, 2020-June 01, 2021</time_frame>
    <description>VCP+H</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Iatrogenic Hypocalcemia</condition>
  <condition>Iatrogenic Hypoparathyroidism</condition>
  <condition>Vocal Cord Paralysis</condition>
  <condition>Vocal Cord Paresis</condition>
  <condition>Vocal Cord; Injury, Superficial</condition>
  <condition>Thyroid Cancer, Papillary</condition>
  <condition>Thyroid Cancer</condition>
  <condition>Multinodular Goiter</condition>
  <condition>Thyroid Neoplasms</condition>
  <condition>Thyroid Nodule</condition>
  <condition>Calcium Deficiency</condition>
  <condition>PTH</condition>
  <arm_group>
    <arm_group_label>Control, s/p TT, without complication</arm_group_label>
    <description>Control (status/post-s/p total thyroidectomy-TT, without complication- demographics and BMI matched)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental, s/p TT with only VCP</arm_group_label>
    <description>Experimental (s/p TT, with only vocal cord paralysis-VCP, uni or bilateral)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental, s/p TT with only H</arm_group_label>
    <description>Experimental (s/p TT, with only hypocalcemia-H, transient or permanent)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental, s/p TT with both VCP+H</arm_group_label>
    <description>Experimental (s/p TT, with both vocal cord paralysis-VCP and hypocalcemia-H);
Subgroups:
4.1. VCP (Permanent) + H (Permanent) 4.2. VCP (Transient) + H (Transient) 4.3. VCP (Permanent) + H (Transient) 4.4. VCP (Transient) + H (Permanent)
Please answer:
Improvement in hypocalcemia also make a positive effect on voice? (any objective sign? Ca? PTH?)
Return of voice is parallel with the improvement in hypocalcemia? (any objective sign? Ca? PTH?</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total thyroidectomy</intervention_name>
    <description>Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.</description>
    <arm_group_label>Control, s/p TT, without complication</arm_group_label>
    <arm_group_label>Experimental, s/p TT with both VCP+H</arm_group_label>
    <arm_group_label>Experimental, s/p TT with only H</arm_group_label>
    <arm_group_label>Experimental, s/p TT with only VCP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with benign or malign thyroid diseases, eligable for total thyroidectomy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with total thyroidectomy indication, for either benign (e.g. multinodular
             goitre) or malign (e.g. thyroid carcinoma) thyroid disease

          -  &gt;17 year-old

          -  Available for close follow-ups at outpatient clinic

          -  Available for close vocal cord exams

        Exclusion Criteria:

          -  Patients with recurrent thyroid disease (benign/malign), prepared for a second
             operation

          -  Preferance of thyroid surgery other than total thyroidectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sema YUKSEKDAG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instructor in General Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ethem UNAL, MD, PhD, USMLE &amp; IFSO-Certified, Board CSS</last_name>
    <role>Study Chair</role>
    <affiliation>Assoc. Professor of General Surgery and Surgical Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ethem UNAL, MD, PhD, USMLE &amp; IFSO-Certified, Board CSS</last_name>
    <phone>0090(216)6321818</phone>
    <phone_ext>1951</phone_ext>
    <email>drethemunal@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kadir YILDIRAK, MD</last_name>
    <phone>0090(216)6321818</phone>
    <phone_ext>1951</phone_ext>
    <email>kadiryildira@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Umraniye Education and Research Hospital, Health Sciences University</name>
      <address>
        <city>Istanbul</city>
        <zip>34764</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethem UNAL, MD, PhD, USMLE &amp; IFSO- Certified Board CSS</last_name>
      <phone>0090(216)6321818</phone>
      <phone_ext>1951</phone_ext>
      <email>drethemunal@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kadir M YILDIRAK, MD</last_name>
      <phone>0090(216)6321818</phone>
      <phone_ext>1951</phone_ext>
      <email>kadiryildira@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sema YUKSEKDAG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>https://www.equator-network.org/reporting-guidelines/strobe/</url>
    <description>STROBE guidelines</description>
  </link>
  <link>
    <url>https://scholar.google.com.tr/citations?user=6bFlCZwAAAAJ&amp;hl=tr</url>
    <description>Ethem Unal, MD, PhD (h-inde 18, i10-index 33)</description>
  </link>
  <link>
    <url>https://www.journalagent.com/ejm/pdfs/EJM-33254-ORIGINAL_ARTICLE-YUKSEKDAG.pdf</url>
    <description>VCP</description>
  </link>
  <link>
    <url>https://books.google.com.tr/books?id=MQX59bsB3CwC&amp;pg=PA606&amp;lpg=PA606&amp;dq=recurrent+nerve+palsy+concurrent+hypocalcemia&amp;source=bl&amp;ots=H0OYiolBHv&amp;sig=ACfU3U1_6EiiCEJ0mBCLikHDHHsoniUxkA&amp;hl=tr&amp;sa=X&amp;ved=2ahUKEwiQpePr_rbpAhUlxMQBHYZdBWYQ6AEwAXoECAUQAQ#v=onepage&amp;q=recurrent%20nerve%20palsy%20concurrent%20hypocalcemia&amp;f=false</url>
    <description>TT complications</description>
  </link>
  <results_reference>
    <citation>Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019 Apr;13(Suppl 1):S31-S34. doi: 10.4103/sja.SJA_543_18. Review.</citation>
    <PMID>30930717</PMID>
  </results_reference>
  <results_reference>
    <citation>Giulea C, Enciu O, Toma EA, Calu V, Miron A. The Tubercle of Zuckerkandl is Associated with Increased Rates of Transient Postoperative Hypocalcemia and Recurrent Laryngeal Nerve Palsy After Total Thyroidectomy. Chirurgia (Bucur). 2019 Sept-Oct;114(5):579-585. doi: 10.21614/chirurgia.114.5.579.</citation>
    <PMID>31670633</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Umraniye Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Ethem Unal, M.D., PhD, Associate Prof of Surgery &amp; Surgic</investigator_full_name>
    <investigator_title>MD, PhD, USMLE &amp; IFSO-Certified, BCSS, Associated Professor of General Surgery and Surgical Oncology</investigator_title>
  </responsible_party>
  <keyword>Total thyroidectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Nodule</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Vocal Cord Paralysis</mesh_term>
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Paresis</mesh_term>
    <mesh_term>Hypocalcemia</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study is open to high-volume INTERNATIONAL endocrine surgery centers, eager to join to present STROBE compatible observational study
Available upon email requests@drethemunal@gmail.com</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>From June 01, 2020, for 6 months</ipd_time_frame>
    <ipd_access_criteria>Contact to drethemunal@gmail.com</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

